Discontinuation of ocrelizumab in multiple sclerosis: reoccurrence of disease activity.

Konen FF, Axhausen F, Wolff S, Mühlenbrock P, Gingele S, Jendretzky KF, Nay S, Grote-Levi LM, Schwenkenbecher P, Meuth SG, Skripuletz T, Pfeuffer S

Open source

DOI: 10.1136/jnnp-2025-337944
Published: 2026 May 14
Container: Journal of neurology, neurosurgery, and psychiatry
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jnnp-2025-337944,
  title = {Discontinuation of ocrelizumab in multiple sclerosis: reoccurrence of disease activity.},
  author = {Konen FF and Axhausen F and Wolff S and Mühlenbrock P and Gingele S and Jendretzky KF and Nay S and Grote-Levi LM and Schwenkenbecher P and Meuth SG and Skripuletz T and Pfeuffer S},
  year = {2026},
  journal = {Journal of neurology, neurosurgery, and psychiatry},
  doi = {10.1136/jnnp-2025-337944},
  url = {https://doi.org/10.1136/jnnp-2025-337944}
}

RIS

TY  - JOUR
TI  - Discontinuation of ocrelizumab in multiple sclerosis: reoccurrence of disease activity.
AU  - Konen FF
AU  - Axhausen F
AU  - Wolff S
AU  - Mühlenbrock P
AU  - Gingele S
AU  - Jendretzky KF
AU  - Nay S
AU  - Grote-Levi LM
AU  - Schwenkenbecher P
AU  - Meuth SG
AU  - Skripuletz T
AU  - Pfeuffer S
PY  - 2026
JO  - Journal of neurology, neurosurgery, and psychiatry
DO  - 10.1136/jnnp-2025-337944
UR  - https://doi.org/10.1136/jnnp-2025-337944
ER  -

APA

FF, K., F, A., S, W., P, M., S, G., KF, J., S, N., LM, G., P, S., SG, M., T, S., & S, P. (2026). Discontinuation of ocrelizumab in multiple sclerosis: reoccurrence of disease activity.. Journal of neurology, neurosurgery, and psychiatry. https://doi.org/10.1136/jnnp-2025-337944

Source records

pubmed · retrieved 2026-09-25T12:41:02.208Z